Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Christina Krupka, Bettina Lindl, Thomas Köhnke, MD, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, MD, Torben Altmann, Peter Kufer, MD, Roman Kischel, MD, Wolfgang Hiddemann, MD, PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 3940.

https://doi.org/10.1182/blood.V128.22.3940.3940

Published: 2016

Journal Articles

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Felix S. Lichtenegger, MD, Katrin Deiser, PhD, Maurine Rothe, Frauke M. Schnorfeil, PhD, Christina Krupka, PhD, Christian Augsberger, Thomas Köhnke, MD, Veit L. Bücklein, MD, Torben Altmann, MD, Andreas Moosmann, Monika Brüggemann, MD PhD, Mirjam H.M. Heemskerk, PhD, Georg Wittmann, MD, Beate Wagner, MD, Wolfgang Hiddemann, MD, Iris Bigalke, PhD, Gunnar Kvalheim, MD PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 764.

https://doi.org/10.1182/blood.V128.22.764.764

Published: 2016

Journal Articles

Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML)

Peter Herhaus, Stefan Habringer, Kathrin Philipp-Abbrederis, Tibor Vag, Carlos Gerngroß, Alexander Höllein, Torben Altmann, Catharina Müller-Thomas, Julia Slotta-Huspenina, Christian Peschel, Markus Schwaiger, Hans-Jürgen Wester, Mareike Verbeek, Karsten Spiekermann, Katharina Götze, Ulrich Keller

Blood (2015) 126 (23): 1275.

https://doi.org/10.1182/blood.V126.23.1275.1275

Published: 2015

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

NARROW

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML)

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only